Top 3 High-Momentum Companies Analysts Are Still Bullish On Compass Therapeutics (NASDAQ:CMPX) Chief Executive Officer Tom ...

TORONTO--(BUSINESS WIRE)--Security Compass, a leading cybersecurity solution provider, has published the results of a research study examining developer views on application security, including the ...

TORONTO--(BUSINESS WIRE)--Security Compass, a leading cybersecurity solution provider, has published the results of a new research report, “2022 DevSecOps Perspectives on AppSec Training”. This study ...

Compass Pathways Plc ((CMPS)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic ...

LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the results from ...

Compass Therapeutics, Inc. (NASDAQ:CMPX) announced statistically significant topline data on Tuesday on the primary efficacy endpoint for COMPANION-002, the company’s ongoing Phase 2/3 trial of ...

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.